Floatz logo

CABAZITAXEL

Metastatic NSCLC

Jules Bordet InstituteSmall moleculePhase 2Dormant
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Metastatic NSCLC cohort.

Asset / SponsorPhaseRating
gme751
Sandoz
Phase 3BB
Grn-1201
BrightPath Biotherapeutics
Phase 2CCC

Same molecule, other indications

CABAZITAXEL is also rated in:

metastatic prostate carcinomaDormant
BB
Indicative ·
68 / 100
View asset →
prostate cancerDormant
BB
Indicative ·
66 / 100
View asset →
prostate adenocarcinomaDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →